Until recently, a chronic lymphocytic leukemia (CLL) diagnosis came with limited options and a lot of uncertainty. Today, long-term results show how much treatment has changed — and what patients and ...

The rapid development of novel agents and combinations in chronic lymphocytic leukemia/small lymphocytic lymphoma has led to multiple options for frontline therapy and relapse, including continuous ...

This tutorial will teach you how to download, install and run a series of biological problems in PhysiCell. Please note that this tutorial will be periodically ...

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States. A study appearing in Clinical Cancer ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...